secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107743
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports Q1 FY2026 net loss $18.2M; Phase 3 sunRIZE topline due Dec 2025
--------------------------------------------------------------------------------

- Cash & marketable securities $152.2M as of Sep 30, 2025, down from $167.9M on Jun 30.
- Net loss $18.2M for Q1 FY2026 vs $15.4M a year ago; R&D $13.1M, G&A $6.7M.
- Phase 3 sunRIZE (congenital HI) topline results expected December 2025; registrational alignment with FDA.
- Streamlined single-arm Phase 3 upLIFT (tumor HI) enrollment underway; topline data H2 2026.
- Virtual investor event Nov 10, 2025 featuring KOLs on commercial opportunity for ersodetug.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925107743/0001104659-25-107743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925107743/tm2529989d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer